ClinicalTrials.gg
RecruitingNCT07058727Updated Nov 16, 2026

Different Hemostatic Agents Used in Partial Pulpotomy on Pulp Survival and Postoperative Pain

An interventional study of Sodium Hypochlorite 2,5% and Chlorhexidine in Efficacy of Hemostatic Agents, Partial Pulpotomy and Postoperative Pain, sponsored by Cukurova University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 15 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Cukurova University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.
Updated Nov 16, 2026Study completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
15 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 33 studies in Pain, Postoperative by Cukurova University — 4 open to participants now, 4 under way, none of them phase 3. Pain, Postoperative · Cukurova University.

Planned enrollment
13th of 33
75 · median 60
Started
2025
with 1 other
No phase
20 of 33
4 open now
Registered
28th of 33
by date

Among the 33 studies in Pain, Postoperative by Cukurova University, this one is the 13th largest by planned enrollment, is one of 2 that started in 2025, is one of 20 with no phase, and was the 28th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

4 of the 33 studies in Pain, Postoperative by Cukurova University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 15 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Pain, Postoperative by Cukurova University, or all of them as a file.
02

Study summary

This randomized clinical trial evaluates the efficacy of sodium hypochlorite (NaOCl), chlorhexidine (CHX), and cold saline as hemostatic agents in partial pulpotomy. The study compares postoperative pain (via VAS scores) and pulp survival (via clinical/radiographic evaluation) at 1, 3, 7 days, 6 months, and 12 months

03

Conditions studied

  • Efficacy of Hemostatic Agents
  • Partial Pulpotomy
  • Postoperative Pain

Browse trials for

04

Who can participate

Ages eligible
15 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Permanent teeth with carious pulp exposure (no spontaneous pain).
  • Positive vitality test (Endo-Ice).
  • No periapical radiolucency.

Exclusion criteria

Exclusion Criteria:

  • Systemic diseases affecting healing.
  • Pregnancy.
  • Non-vital pulp/necrosis
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    Arm 1

    2.5% NaOCl applied for 1 min after pulp exposure.

    Drug: Sodium Hypochlorite 2,5%

  • Experimental
    Arm 2

    2% CHX applied for 1 min

    Drug: Chlorhexidine

  • Experimental
    Arm 3

    Hemostasis achieved with 4°C saline for 1 min.

    Drug: Cold Saline

Interventions

  • DrugSodium Hypochlorite 2,5%

    2.5% NaOCl applied for 1 min to exposed pulp for hemostasis, followed by standard pulp capping

  • 2% CHX applied for 1 min to achieve hemostasis, with identical subsequent steps to NaOCl group

  • DrugCold Saline

    Hemostasis via 4°C saline (1 Min), then standardized pulp capping

06

What researchers measure

Primary outcomes

  1. Postoperative Pain

    The patient will be asked to rate the pain on the 1st, 3rd and 7th day according to VAS. (The patient is asked to score their pain in this range, with 0 being the lowest and 10 being the highest.)

    Time frame: 1 week

  2. Pulp Survival Rate

    The pulp is expected to be vital, without percussion tenderness and without spontaneous pain

    Time frame: 12 months

Secondary outcomes

  1. Clinical Success

    Maintaining the integrity of the restoration No need for endodontics treatments

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2025 to primary completion in Nov 2025, 6 months.

Of 2,113 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's 6 months is below that.

Counting every sponsor, half of 2,126 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

Completion moved once since we started tracking on Sep 25, 2026: May 2026 → Mar 2027, on Nov 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2025
First posted
Jul 10, 2025
StartActual
May 1, 2025
Primary completionActual
Nov 1, 2025
CompletionEst.
Mar 1, 2027was May 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Study completion
May 1, 2026→Mar 1, 2027
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Study completion May 1, 2026→Mar 1, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07058727
Responsible party
Zehra SUSGUN YILDIRIM (Principal Investigator, Cukurova University) — Principal investigator
First posted
Jul 10, 2025
Start date
May 1, 2025
Primary completion
Nov 1, 2025
Completion
Mar 1, 2027 (estimated)
Last update
Nov 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Chlorhexidine

Start the discussion